WRITTEN BY
We are welcoming Thermo Fisher Scientific to join the AstraZeneca BioVentureHub at AstraZeneca’s R&D centre in Gothenburg
The PPD™ clinical research business of Thermo Fisher Scientific, the world leader in serving science, today announced a new research and development (R&D) partnership with, and move into, the AstraZeneca BioVentureHub in Gothenburg, Sweden.
The partnership aims to leverage the combined expertise of Thermo Fisher Scientific and AstraZeneca to drive innovation and strengthen the life science ecosystem. A dedicated team from Thermo Fisher Scientific will co-locate with AstraZeneca scientists to work on collaborative R&D projects with a focus initially on chromatography, molecular genomics and proteomics.
From the left: Ulrika Edvardsson, Senior Director and Managing Director AstraZeneca BioVentureHub, Niveen Mullholland, Vice President, Bioanalytical and Vaccine Services, Thermo Fisher Scientific, Leon Wyszkowski, President, Analytical Services, Clinical Research, Thermo Fisher Scientific, Robert Roth, Science Director, AstraZeneca BioVentureHub, and Frauke Graalfs, Director, Enterprise Science and Innovation, Global Corporate Accounts, Thermo Fisher Scientific.
"This is a unique opportunity to co-locate with AstraZeneca scientists, driving collaborative innovation, strengthening the science ecosystem and driving value generation for all collaborators, giving easy access to cutting edge technologies for emerging life sciences and biotech companies as well as academic groups,” said Leon Wyszkowski, President, Analytical Services, Clinical Research, Thermo Fisher Scientific. “This partnership will enable advancements in areas such as drug and analytical development, further bringing to life Thermo Fisher Scientific's mission to enable our customers to make the world healthier, cleaner and safer."
“When two global life science leaders join forces in an open innovation environment, truly exceptional conditions for breakthrough discovery and progress are created. Welcoming Thermo Fisher Scientific into BioVentureHub at AstraZeneca’s strategic R&D centre in Gothenburg - adjacent to GoCo Health Innovation City - marks a significant step and unlocks dynamic opportunities for open scientific co-creation between AstraZeneca and Thermo Fisher Scientific. We are pleased to welcome the Thermo Fisher Scientific's team and look forward to a highly productive partnership," Magnus Björsne, CEO, AstraZeneca BioVentureHub said.
The AstraZeneca BioVentureHub is part of a growing innovation ecosystem in Gothenburg that includes the GoCo Health Innovation City, future home of Thermo Fisher Scientific's bioanalytical laboratory that is under construction and expected to begin operations in March 2026. This state-of-the-art facility will serve pharmaceutical and biotech customers in Europe and across the globe, providing leading-edge bioanalytical laboratory capabilities to support all phases of pharmaceutical development to help customers deliver life-changing medicines to patients worldwide.
In addition to the new lab coming online in Sweden, the business operates a global network of GMP (good manufacturing practices), central, bioanalytical and vaccine science laboratories with operations based in Middleton, Wisconsin; Highland Heights, Kentucky; Richmond, Virginia; Athlone, Ireland; Brussels, Belgium; Singapore; and Suzhou, China.
The BioVentureHub and Thermo Fisher Scientific teams, setting up the collaboration, together with AstraZeneca expertise.
From the left: Robert Roth, Science Director, AstraZeneca BioVentureHub, Ulrika Edvardsson, Senior Director and Managing Director AstraZeneca BioVentureHub, Frauke Graalfs, Director, Enterprise Science and Innovation, Global Corporate Accounts, Thermo Fisher, Scientific, and Ryan Hicks, Site Lead - Thermo Fisher Scientific Bioanalytical Labs, Gothenburg, Sweden.
Read more about Thermo Fisher Scientific here: www.ppd.com
Read more about Thermo Fisher Scientific on Linkedin: Click here.
Follow AstraZeneca BioVentureHub on Linkedin: Click here.
Subscribe to the BioVentureHub Newsletter: Sign up here.